ClinicalTrials.gov
public full text
Public Domain
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
The goal of this observational study is to valuate the sensitivity and specificity of different blood biomarkers for monitoring and assessing Aβ-PET-confirmed mitigation of amyloid pathology by lencanumab treatment in subjects treated with lencanumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics#161197
- Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients#1310003
- Daratumumab for the Treatment of Patients With AL Amyloidosis#1047466
- A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients#1293481
- An Open-Label Crenezumab Study in Participants With Alzheimer's Disease#1162908
Record · ID 1384308
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive